About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a leader in hematology/oncology.
Our primary strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to building an efficient in-house clinical development organization with regulatory and data management capabilities, Spectrum has established a commercial infrastructure for its marketed products. We have five oncology/hematology products on the market, three for different types of non-Hodgkin's lymphoma, one for advanced metastatic colorectal cancer, and one for a specific type of acute lymphoblastic leukemia (ALL). Spectrum also has two drugs in late stage development: Evomela™ (melphalan hydrochloride) for injection and apaziquone. Spectrum also has a diverse pipeline including SPI-2012 — an asset of potentially significant value. We also leverage the expertise of our worldwide partners to assist in the execution of our strategy.
Our passion to identify, develop and deliver important options for people suffering from cancer is behind every action we take. At Spectrum, we are committed to excellence and strive to make a difference in the lives of patients every day.
The Key is our People
Collectively, the members of our team have relevant experience in both the development and marketing of oncology drugs and the growth of profitable business ventures.
Our Goal is to Bring Quality Drugs to Patients
Spectrum Pharmaceuticals actively seeks and evaluates potentially important drug candidates. Once we identify these candidates, we rapidly assess preclinical and clinical data, and the commercialization potential of candidates. Then through both in-licensing and co-development partnerships, we provide the expertise and neccesary funding to bring the most promising products through the complex development process to market.
In order to maximize the commercial potential of our current and future drugs, Spectrum has assembled a distinguished Commercial Team that was recruited from the top sales performers in the oncology specialty arena, and who are dedicated to bringing important, quality treatments to cancer patients.
You may contact Spectrum's Compliance Officer at any time at: firstname.lastname@example.org